Announcement under Regulation 30 (LODR)-Change in Management
Filed with BSE · · 3 pages · English
Summary by 6ix AI
Asston Pharmaceuticals Limited has filed a notification regarding changes in management and financial approvals following their recent annual general meeting. The company has approved the re-appointment of its Managing Director and the appointment of new statutory auditors. Additionally, there are increases in remuneration for several directors, including the Managing Director and the Whole-time Director.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
1. Receipt, consideration and adoption of the Audited Standalone financial statements of the Company for the financial year ended March 31, 2026 together with the reports of Board of Directors and of the Auditors thereon. 3. Approved appointment of M/s Panchal S K & Associates (Peer Review Certificate No. 018089 and Firm Registration No. 145989W) as Statutory Auditors of the Company (Annexure-B).
Asston Pharmaceuticals Limited on 6ix
Earlier from Asston Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- Asston Pharmaceuticals Limited Press Release Sep 29 2026
- Asston Pharmaceuticals Limited Press Release Sep 27 2026
- Asston Pharmaceuticals Limited Press Release Sep 07 2026
Later from Asston Pharmaceuticals
- Board Meeting Intimation for To Consider And Approve The Following Matters As Attached
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Follow Asston Pharmaceuticals into a list and get an email when it puts out news.
Follow Asston Pharmaceuticals